FR2601014B1 - Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation - Google Patents

Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation

Info

Publication number
FR2601014B1
FR2601014B1 FR878709316A FR8709316A FR2601014B1 FR 2601014 B1 FR2601014 B1 FR 2601014B1 FR 878709316 A FR878709316 A FR 878709316A FR 8709316 A FR8709316 A FR 8709316A FR 2601014 B1 FR2601014 B1 FR 2601014B1
Authority
FR
France
Prior art keywords
preparing
composition
same
crystalline hydrate
oral cephalosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR878709316A
Other languages
English (en)
French (fr)
Other versions
FR2601014A1 (fr
Inventor
Yoshio Hamashima
Kyoji Minami
Kyozo Kawata
Teruo Sakamoto
Toyohiko Takeda
Yusuke Suzuki
Masanori Tujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of FR2601014A1 publication Critical patent/FR2601014A1/fr
Application granted granted Critical
Publication of FR2601014B1 publication Critical patent/FR2601014B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
FR878709316A 1986-07-02 1987-07-01 Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation Expired - Lifetime FR2601014B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (2)

Publication Number Publication Date
FR2601014A1 FR2601014A1 (fr) 1988-01-08
FR2601014B1 true FR2601014B1 (fr) 1990-09-14

Family

ID=26484565

Family Applications (1)

Application Number Title Priority Date Filing Date
FR878709316A Expired - Lifetime FR2601014B1 (fr) 1986-07-02 1987-07-01 Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation

Country Status (27)

Country Link
US (2) US4812561A (enExample)
KR (1) KR950005302B1 (enExample)
CN (1) CN1015106B (enExample)
AR (1) AR243893A1 (enExample)
AT (1) AT392472B (enExample)
AU (1) AU594167B2 (enExample)
BE (1) BE1001691A4 (enExample)
CA (1) CA1283405C (enExample)
CH (1) CH672788A5 (enExample)
DE (1) DE3721913A1 (enExample)
DK (1) DK161080C (enExample)
ES (2) ES2004952A6 (enExample)
FI (1) FI89052C (enExample)
FR (1) FR2601014B1 (enExample)
GB (1) GB2192183B (enExample)
GR (1) GR871014B (enExample)
HK (1) HK47893A (enExample)
HU (1) HU200777B (enExample)
IE (1) IE59613B1 (enExample)
IL (1) IL83059A (enExample)
IT (1) IT1211469B (enExample)
NL (1) NL193136C (enExample)
NO (1) NO170889C (enExample)
NZ (1) NZ220764A (enExample)
PL (1) PL159180B1 (enExample)
RU (1) RU1829932C (enExample)
SE (1) SE466257B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
CA2134467A1 (en) * 1992-04-30 1993-11-11 Donald Johnson Stable hydrated cephalosporin dry powder for oral suspension formulation
CA2314140A1 (en) * 1998-10-27 2000-05-04 Randal Ray Ford Process for the polymerization of olefins; novel polyethylenes, and films and articles produced therefrom
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008082488A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
AU2007339382B2 (en) 2006-12-22 2013-05-02 Merck Sharp & Dohme Llc 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
JP5272007B2 (ja) * 2007-08-29 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症を治療するための２，３−置換インドール誘導体
US8404845B2 (en) 2007-08-29 2013-03-26 Merck Sharp & Dohme Corp. 2,3-substituted azaindole derivatives for treating viral infections
WO2009032124A1 (en) * 2007-08-29 2009-03-12 Schering Corporation Substituted indole derivatives and methods of use thereof
MX2010005355A (es) * 2007-11-16 2010-06-02 Schering Corp Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
CA2705586A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
EP2303893B1 (en) * 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201019939A (en) 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8609635B2 (en) 2010-03-09 2013-12-17 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EP2566449B1 (en) 2010-05-04 2014-10-08 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
EP2833874A1 (en) * 2012-04-04 2015-02-11 Mahmut Bilgic Capsule formulations comprising ceftibuten
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (en) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten capsule compositions
WO2017197371A1 (en) 2016-05-13 2017-11-16 Aeromics, Inc. Crystals
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
EP4362950A4 (en) * 2021-07-01 2025-08-13 Qpex Biopharma Inc CRYSTALLINE FORMS OF CEFTIBUTEN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Also Published As

Publication number Publication date
IT1211469B (it) 1989-11-03
PL159180B1 (pl) 1992-11-30
SE8702705L (sv) 1988-01-03
SE8702705D0 (sv) 1987-06-30
NO170889B (no) 1992-09-14
NO872729D0 (no) 1987-06-30
AT392472B (de) 1991-04-10
GB8715064D0 (en) 1987-08-05
HU200777B (en) 1990-08-28
IT8767566A0 (it) 1987-07-01
AU7504087A (en) 1988-01-07
KR950005302B1 (ko) 1995-05-23
SE466257B (sv) 1992-01-20
FR2601014A1 (fr) 1988-01-08
NZ220764A (en) 1989-09-27
CH672788A5 (enExample) 1989-12-29
DK161080C (da) 1991-11-11
NO170889C (no) 1992-12-23
AU594167B2 (en) 1990-03-01
KR880001670A (ko) 1988-04-26
GR871014B (en) 1987-11-02
ATA165887A (de) 1990-09-15
HK47893A (en) 1993-05-27
PL266567A1 (en) 1988-07-21
RU1829932C (ru) 1993-07-23
IE871738L (en) 1988-01-02
CN1015106B (zh) 1991-12-18
IL83059A0 (en) 1987-12-31
IL83059A (en) 1992-03-29
CN87105009A (zh) 1988-03-23
BE1001691A4 (fr) 1990-02-13
FI872903A0 (fi) 1987-07-01
GB2192183A (en) 1988-01-06
DK336487D0 (da) 1987-06-30
DK336487A (da) 1988-01-03
NO872729L (no) 1988-01-04
NL193136C (nl) 1998-12-04
NL8701507A (nl) 1988-02-01
FI89052B (fi) 1993-04-30
US4933443A (en) 1990-06-12
HUT44257A (en) 1988-02-29
FI89052C (fi) 1993-08-10
AR243893A1 (es) 1993-09-30
IE59613B1 (en) 1994-03-09
ES2004952A6 (es) 1989-02-16
CA1283405C (en) 1991-04-23
FI872903L (fi) 1988-01-03
NL193136B (nl) 1998-08-03
ES2008759A6 (es) 1989-08-01
GB2192183B (en) 1990-05-16
US4812561A (en) 1989-03-14
DK161080B (da) 1991-05-27
DE3721913A1 (de) 1988-01-07

Similar Documents

Publication Publication Date Title
FR2601014B1 (fr) Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation
HUT44553A (en) Process for preparing crystalline carbapenem derivatives
PT82794A (en) Process for preparing 3-phenyl-4-cyanopyrrole derivatives useful as microbicides
PT86309A (en) Process for the preparation of substituted basic 2-aminotetralins
HU906232D0 (en) Process for the preparation of pyridile derivatives
PT84938A (en) Process for the preparation of imidazoquinolinylether derivatives
PT86800A (pt) Process for the preparation of erythromycin derivatives
FI90942B (fi) Kiinteän, kiteisen nedokromiilinatriumin valmistusmenetelmä
NO170581C (no) Fremgangsmaate for fremstilling av vannfritt, krystallinsknatriumsalt av 5-klor-3-(2-tenoyl)-2-oksindol-1-karboksamid
NO842214L (no) Fremgangsmaate for fremstilling av antibakterielle cefalosporinderivater.
MA20250A1 (fr) Procede de preparation de derives de cephalosporine.
PT81840A (en) Process for the production of cephem derivatives useful as antibacterial agents
GR3017917T3 (en) Crystalline addition salts of cephem compounds and process for their preparation.
HU885893D0 (en) Process for the preparation of substituted azaciclohexyl derivatives
GB2152497B (en) Process for the preparation of azetidinone derivatives
PT86899A (pt) Process for preparing 27-halo derivatives of ll-f28249 compounds
FI850969A7 (fi) Monosilyloituja aminofenyylietyyliamiinijohdannaisia, menetelmä niiden valmistamiseksi niiden käyttö kasvun edistämiseksi
HUT43245A (en) Compounds containing as active substance hindering pollen formation derivatives of pirasole and process for production of the active substance
IL90635A0 (en) Process for the preparation of quinoline antibacterial compounds
EP0373216A4 (en) Cephalosporin compounds or their salts, process for their preparation, and parmaceutical compositions
PT88465A (pt) Process for the preparation of macrolide compounds
PT88467A (pt) Process for the preparation of macrolide compounds
AU8213787A (en) Process for the preparation of crystalline calcium sodium metaphosphate
FI92393B (fi) Menetelmä 1,5-bentsotiatsepiinijohdannaisten valmistamiseksi
NO872825L (no) FremgangsmŸte for fremstilling av antibakterielt aktive cefalosporinderivater.